Table 1. Clinical outcome in sickle cell... | American Society of Hematology

Table 1.

Clinical outcome in sickle cell disease patients before and during hydroxyurea therapy

	Before HU	After 1 y HU	After 2 y HU	After 3 y HU	After 4 y HU	After 5 y HU
No. of evaluable patients	93^*	82	61	44	33	22
No. of hospitalizations per year (mean ± SD)	2.76 ± 2.3	1.15 ± 1.9^1-153	1.08 ± 1.5^1-153	1.11 ± 1.5^1-153	1.33 ± 2.1^1-155	1.2 ± 1.5^‡
No. of days in hospital (mean ± SD)	18.1 ± 17.3	7.3 ± 15.8^1-153	5.4 ± 9^1-153	4.9 ± 7.2^1-153	9.1 ± 13.3^‡	9.4 ± 13^†

	Before HU	After 1 y HU	After 2 y HU	After 3 y HU	After 4 y HU	After 5 y HU
No. of evaluable patients	93^*	82	61	44	33	22
No. of hospitalizations per year (mean ± SD)	2.76 ± 2.3	1.15 ± 1.9^1-153	1.08 ± 1.5^1-153	1.11 ± 1.5^1-153	1.33 ± 2.1^1-155	1.2 ± 1.5^‡
No. of days in hospital (mean ± SD)	18.1 ± 17.3	7.3 ± 15.8^1-153	5.4 ± 9^1-153	4.9 ± 7.2^1-153	9.1 ± 13.3^‡	9.4 ± 13^†

HU indicates hydroxyurea.

78 patients of 93 registered are evaluable for hospitalizations in the year before their entry in the registry.

P value not significant, when compared to baseline.

P < .05, when compared to baseline.

P < .01, when compared to baseline.

P < .02, when compared to baseline.